Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases – A ten year study
Authors:
- J.T. LordanJLJ.T. Lordan
- 31 August 2009
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 35 (8) , 838-843
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal CancerSeminars in Oncology, 2006
- Current role of radiofrequency ablation for the treatment of colorectal liver metastasesBritish Journal of Surgery, 2006
- A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200Annals of Oncology, 2006
- Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studiesBritish Journal of Cancer, 2006
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Late results justify resection for multiple hepatic metastases from colorectal cancerBritish Journal of Surgery, 1997
- Factors influencing the natural history of colorectal liver metastasesThe Lancet, 1994
- Surgical treatment of liver metastases in patients with colorectal cancerCancer, 1993
- Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectumDiseases of the Colon & Rectum, 1982